Regeneron Pharma Extends Agreement With BARDA, Part Of ASPR Within US Department Of HHS, To Provide Additional Supply Of Inmazeb For US Preparedness Against Ebola Disease
Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense, adding value of approximately $270 millionTARRYTOWN, N.Y., Oct. 26,
Regeneron got a bigger contract to supply Ebola medicine to the US government. This shows people trust the company's medicine and need it ready for emergencies.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.